November 12 2019 - AstraZeneca plans 2020 filing for lupus drug
Flag link:
AstraZeneca plans 2020 filing for anifrolumab in lupus
AstraZeneca plans 2020 filing for anifrolumab in lupus
Fierce Biotech
AstraZeneca
FDA
lupus
anifrolumab
Flag link:
Lonza leader Marc Funk quits after just 9 months as CEO
Lonza leader Marc Funk quits after just 9 months as CEO
Fierce Pharma
Lonza
Pharma CEOs
Marc Funk
Flag link:
Reata's bardoxolone offers promise in patients with rare kidney disorder
Reata's bardoxolone offers promise in patients with rare kidney disorder
Endpoints
Reata Pharmaceuticals
Bardoxolone
chronic kidney disease
Alport syndrome
Flag link:
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
Yahoo/Zacks.com
earnings
biotech
Eyenovia
SAGE Therapeutics
AC Immune
Ascendis
NGM Biopharmaceuticals
Flag link:
Servier reveal how they are using data to empower their field force
Servier reveal how they are using data to empower their field force
Pharmaforum
Servier
drug reps
CRM
digital pharma
Flag link:
Shares of Amarin rise on favorable opinion from FDA committee
Shares of Amarin rise on favorable opinion from FDA committee
Marketwatch
FDA
Amarin
Vascepa
Flag link:
GSK must continue to improve R&D, says CEO Walmsley
GSK must continue to improve R&D, says CEO Walmsley
Pharmaforum
GSK
R&D
Emma Walmsley
Pharma CEOs
Flag link:
Amgen to cut 149 staff in retreat from neuroscience R&D
Amgen to cut 149 staff in retreat from neuroscience R&D
Fierce Biotech
Amgen
Neuroscience
layoffs
R&D
Flag link:
Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data
Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data
Fierce Pharma
JNJ
Tremfya
psoriatic arthritis
psoriasis
clinical trials
Flag link:
Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity
Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity
Stat
Solid Biosciences
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
SGT-001
Flag link:
Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data
Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data
Fierce Pharma
Eli Lilly
Taltz
psoriatic arthritis
AbbVie
Humira
Flag link:
Safety qualms in MyoKardia mid-stage study cause investors to pause
Safety qualms in MyoKardia mid-stage study cause investors to pause
Endpoints
MyoKardia
obstructive hypertrophic cardiomyopathy
clinical trials
mavacamten
Flag link:
It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill
It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill
Stat
drug pricing
biotech
legislation
Nancy Pelosi
Flag link:
FDA rejects Lipocine's testosterone drug for third time
FDA rejects Lipocine's testosterone drug for third time
Reuters
FDA
Lipocine
low testosterone
Tlando
Flag link:
Roche tests 'brain shuttle' in humans in Alzheimer's project
Roche tests 'brain shuttle' in humans in Alzheimer's project
Reuters
Roche
Alzheimer's disease
monoclonal antibodies
gantenerumab
Flag link:
With Allergan megamerger looming, AbbVie plots massive $28B bond offering: Bloomberg
With Allergan megamerger looming, AbbVie plots massive $28B bond offering: Bloomberg
Fierce Pharma
AbbVie
Allergan
M&A
Flag link:
What has Zantac recall cost drugmakers? Dr. Reddy's gives a hint
What has Zantac recall cost drugmakers? Dr. Reddy's gives a hint
Fierce Pharma
Zantac
OTC
product recalls
generics
Dr Reddy's
Flag link:
The Ebola Vaccine Is Now Officially Here With Approval In Europe
The Ebola Vaccine Is Now Officially Here With Approval In Europe
Forbes
Europe
ebola virus
vaccines
Merck
Ervebo
Flag link:
SITC – the morning after the night before
SITC – the morning after the night before
EP Vantage
SITC
NextCure
Pieris
Celyad
Nektar
Flag link:

Pages